PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC announced on January 6, 2011 the results of its Phase I clinical study of its unique formulation of naproxen, a widely used pain medication, using its proprietary, patented nanotechnology. The comparator product used in this Phase I pharmacokinetic study of naproxen was identified as Naprosyn®. The comparator product used in the study was EC-Naprosyn®, a currently marketed enteric-coated brand of naproxen.
